<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

The Role of Patient-Derived Tumor Organoids in Precision Medicine

patient-derived tumor organoids in precision medicineExplore how patient-derived tumor organoids are used in the clinic to develop novel precision medicine approaches for guiding and informing treatment options.

What Are Patient-Derived Tumor Organoids?

Patient-derived tumor organoids are a transformative preclinical oncology model system. 3D organoids are derived directly from patient tumor tissue, using culture conditions specifically designed to preserve the cancer stem cell (CSC) component of the originating tumor. As a result, organoids faithfully recapitulate originating tumor complexity, due to the CSCs ability for self-renewal and differentiation into the multiple cell types found in the original tumor.

Hubrecht Organoid Technology (HUB) protocols, based on methods first developed in the Clevers lab, are pioneering protocols for developing patient-derived tumor organoids. These methods employ a cocktail of growth factors, without a feeder cell layer to generate robust tumor organoids, closely recapitulating several properties of the original tumor.

Tumor Organoids Recapitulate the Original Tumor Tissue

Patient-derived tumor organoids contain both CSCs and their downstream, more-differentiated progeny. Tumor organoids also share genomic characteristics with their primary tumor. For example, pancreatic tumor organoids have been shown to maintain oncogenic alterations (e.g. KRAS, TP53, SMAD, CDKN2A, amplified MYC) and loss of tumor suppressors TGFBR2 and DCC.

Tumor organoids also exhibit morphologic structures reminiscent of primary tumor histology, e.g. pancreatic, colon, breast, prostate, lung, liver, etc. This can include developing an invasive phenotype typical of metastatic tumors. Gene and protein expression are also similar to those seen in corresponding primary tumor cell subtypes.

Tumor Organoids Enable Precision Medicine Approaches

Precision medicine is being increasingly used in oncology to help select the best therapy for a specific patient. While patient-derived xenografts (PDX) showed some promise for precision medicine, they take time to develop, can be costly, and are not easily scaled.

Since tumor organoids are also patient-derived models, they are similar to PDX in that they preserve original tumor characteristics and patient relevance, as well as being predictive of patient treatment response. The added benefits of tumor organoids over PDX for enabling precision medicine approaches is that they are faster to develop and more easily scalable.

Tumor organoids allow the testing of a wide variety of possible therapies, many of which might not be standard of care for the indication in question. These results can potentially be combined with other tests, like genomic screens, to determine mechanisms of resistance or alternative therapeutic options.

A typical workflow for these types of studies is:

  • Establish patient-derived tumor organoids using biopsies obtained from cancer patients, which may be treatment naïve or have failed previous therapies
  • Establish and expand the tumor organoid cultures
  • Perform in vitro screens using the tumor organoids and a variety of anticancer treatments (alone or in combination), such as chemotherapies, radiation, etc.
  • Inform clinicians on the lab findings

pdx vs tumor organoid workflow in precision medicine

Some technical and translational considerations need to be kept in mind when comparing ex vivo organoid and patient response. Firstly, not all tumors will develop into organoids - the take rate, for example, is lower for low grade tumors.

Additionally, organoid culture conditions are optimized for epithelial, therefore the tumor microenvironment contribution to tumor therapy response can’t be evaluated unless autologous immune cells and stroma are also available. Autologous organoid and immune cell co-cultures are currently being researched, but it’s early days. Protocols still need to be optimized for multiple tumor and immune cell types before they can be applied to evaluating patient response.

Clinical Trials Using Tumor Organoids

Clinical trials using tumor organoids as a readout fall into two main categories:

  1. Guiding patient treatment options. In these trials tumor organoids are established from cancer patients, and drug sensitivity data are used to guide treatment options for these patients in real time. Treatment options are devised based on the tumor organoid drug sensitivity data.

    For example, an upcoming innovative clinical trial (the ORGANOTREAT-01 trial run by the Gustave Roussy/INSERM in Paris) proposes to use tumor organoids to generate a personalized chemogram for patients, and identify unexpected therapeutic options for them. Biopsies will be taken from patients with advanced colorectal cancer and other digestive cancers as they are finishing their last line of treatment.

    The resulting patient-derived tumor organoids will then be used to test a panel of 26 treatments to evaluate antitumor activity within 6 weeks, and suggest additional or alternative therapies as quickly as possible. A secondary objective is to evaluate the proportion of patients treated according to the chemograms, and the efficacy of the different regimens.

  2. Informing on treatment options for subsequent patients with shared tumor characteristics. In these trials, patients and their derived tumor organoids are treated with the same drug regimens. Clinical outcomes and tumor organoid drug sensitivity data are then compared. The main goal of these studies is to use the data downstream, to inform treatment options for later patients with shared tumor characteristics.

    A recent co-clinical study developed metastatic colorectal cancer organoids to evaluate the drug response in the organoids compared to the patient they were derived from. Across targeted agents and chemotherapy the organoids had a 100% negative predictive value and 89% positive predictive power, demonstrating the clinical relevance of tumor organoids.

Conclusion

Patient-derived tumor organoids are positioned to transform cancer precision medicine due to their faithful recapitulation of parental tumor complexity, and their amenability for rapid, multi agent testing. These ongoing clinical trials will validate the applicability of tumor organoids for precision medicine, allowing guidance of patient treatment.


Related Posts